Early discontinuation and suboptimal dosing of duloxetine treatment in patients with major depressive disorder: Analysis from a US third-party payer perspective

Journal of Medical Economics

Volumn 15, Issue 1, 2012, Pages 134-144

  Cui, Zhanglin ^a   Faries, Douglas E ^a   Gelwicks, Steven ^a   Novick, Diego ^a   Liu, Xianchen ^b  

^a ELI LILLY AND COMPANY   (United States)

^b INDIANA UNIVERSITY   (United States)

Author keywords

Attrition; Duloxetine; Health outcome; Major depressive disorder; Predictor

Indexed keywords

BENZODIAZEPINE; DULOXETINE; SEROTONIN UPTAKE INHIBITOR; VENLAFAXINE;

ADULT; AGED; DIGESTIVE SYSTEM FUNCTION DISORDER; FEMALE; FOLLOW UP; GROUPS BY AGE; HEALTH CARE COST; HOSPITAL ADMISSION; HOSPITALIZATION; HUMAN; INFECTION; INSOMNIA; INTOXICATION; MAJOR CLINICAL STUDY; MAJOR DEPRESSION; MALE; MENTAL DISEASE; REVIEW; SEX DIFFERENCE; UNITED STATES; UROGENITAL TRACT DISEASE;

ADOLESCENT; ADULT; AGED; ANTIDEPRESSIVE AGENTS; DEPRESSIVE DISORDER, MAJOR; DOSE-RESPONSE RELATIONSHIP, DRUG; FEMALE; HUMANS; INSURANCE, HEALTH, REIMBURSEMENT; LOGISTIC MODELS; MALE; MIDDLE AGED; THIOPHENES; UNITED STATES; WITHHOLDING TREATMENT; YOUNG ADULT;

EID: 84862937906     PISSN: 13696998     EISSN: 1941837X     Source Type: Journal    
DOI: 10.3111/13696998.2011.632043     Document Type: Review

References (25)

1. U.S. Census Bureau Population Estimates by Demographic Characteristics. Table 2: annual estimates of the population by selected age groups and sex for the United States: 1 April 2000 to 1 July 2004. Population Division, U.S. Census Bureau: 9 June 2005
2. Caley CF, Kando JC. SSRI efficacy-finding the right dose. J Psychiatr Pract 2002;8:33-40
3. American Psychiatric Association. Practice guideline for the treatment of patients with major depressive disorder. 3rd edn. Am J Psychiatry 2010; 167(Suppl):1-152
4. Warden D, Trivedi MH, Wisniewski SR, et al. Predictors of attrition during initial (citalopram) treatment for depression: a star*d report. Am J Psychiatry 2007;164:1189-97 (Pubitemid 47292407)
5. Detke MJ, Lu Y, Goldstein DJ, et al. Duloxetine, 60 mg once daily, for major depressive disorder: a randomized double-blind placebo-controlled trial. J Clin Psychiatry 2002;63:308-15 (Pubitemid 34456358)
6. Detke MJ, Wiltse CG, Mallinckrodt CH, et al. Duloxetine in the acute and long-term treatment of major depressive disorder: a placebo-and paroxetine-controlled trial. Eur Neuropsychopharmacol 2004;14:457-70 (Pubitemid 39626894)
7. Demyttenaere K, Van Ganse E, Gregoire J, et al. Compliance in depressed patients treated with fluoxetine or amitriptyline. Belgian Compliance Study Group. Int Clin Psychopharmacol 1998;13:11-17 (Pubitemid 28092265)
8. Demyttenaere K, Enzlin P, Dewe W, et al. Compliance with antidepressants in a primary care setting, 1: beyond lack of efficacy and adverse events. J Clin Psychiatry 2001;62(22 Suppl):30-3 (Pubitemid 32937583)
9. Arnow BA, Blasey C, Manber R, et al. Dropouts versus completers among chronically depressed outpatients. J Affect Disord 2007;97:197-202 (Pubitemid 44937434)
10. Eaddy MT, Druss BG, Sarnes MW, et al. Relationship of total health care charges to selective serotonin reuptake inhibitor utilization patterns including the length of antidepressant therapy-results from a managed care administrative claims database. J Manag Care Pharm 2005;11:145-50
11. Melfi CA, Chawla AJ, Croghan TW, et al. The effects of adherence to anti-depressant treatment guidelines on relapse and recurrence of depression. Arch Gen Psychiatry 1998;55:1128-32 (Pubitemid 28558286)
12. Eaddy M, Bramley T, Regan T. Time to antidepressant discontinuation: a comparison of controlled-release paroxetine and immediate-release selective serotonin-reuptake inhibitors. Manag Care Interface 2003;16:22-7 (Pubitemid 38067347)
13. Liu X, Tepper PG, Able SL. Adherence and persistence with duloxetine and hospital utilization in patients with major depressive disorder. Int Clin Psychopharmacol 2011;26:173-80
14. Liu XC, Gelwicks S, Faries D, et al. Initial duloxetine prescription dose and treatment adherence and persistence in patients with major depressive disorder. Int Clin Psychopharmacology 2010;25:315-22
15. Bull SA, Hu XH, Hunkeler EM, et al. Discontinuation of use and switching of antidepressants: influence of patient-physician communication. JAMA 2002;288:1403-9 (Pubitemid 35025915)
16. Warden D, Trivedi MH, Wisniewski SR, et al. Predictors of attrition during initial (citalopram) treatment for depression: a STAR*D report. Am J Psychiatry 2007;164:1189-97 (Pubitemid 47292407)
17. Detke MJ, Wiltse CG, Mallinckrodt CH, et al. Duloxetine in the acute and long-term treatment of major depressive disorder: a placebo-and paroxetine-controlled trial. Eur Neuropsychopharmacol 2004;14:457-70 (Pubitemid 39626894)
18. Kornstein SG, Dunner DL, Meyers AL, et al. A randomized, double-blind study of increasing or maintaining duloxetine dose in patients without remission of major depressive disorder after initial duloxetine therapy. J Clin Psychiatry 2008;69:1383-92
19. Cymbalta package insert. Indianapolis, IN: Eli Lilly and Company, 2011. Available at: http://pi.lilly.com/us/cymbalta-pi.pdf. Accessed June 27, 2011
20. Liu X, Gelwicks S, Able S, et al. Initial high-dose prescription of duloxetine in patients with major depressive disorder: demographic and clinical predictors. Presented at: ISPOR 12th Annual European Congress, Paris, France, 26 October 2009
21. Liu XC, Cui Z, Niu L, et al. Dosing patterns for duloxetine and predictors of high-dose prescriptions in patients with major depressive disorder: analysis from a United States third-party payer perspective. Clin Ther In Press
22. Detke MJ, Lu Y, Goldstein DJ, et al. Duloxetine 60 mg once daily dosing versus placebo in the acute treatment of major depression. J Psychiatr Res 2002;36:383-90 (Pubitemid 35254112)
23. Perahia DG, Wang F, Mallinckrodt CH, et al. Duloxetine in the treatment of major depressive disorder: a placebo-and paroxetine-controlled trial. Eur Psychiatry 2006;21:367-78
24. Nelson JC, Lu Pritchett Y, Martynov O, et al. The safety and tolerability of duloxetine compared with paroxetine and placebo: a pooled analysis of 4 clinical trials. Prim Care Companion J Clin Psychiatry 2006;8:212-9 (Pubitemid 44371559)
25. Motheral BR, Cox ER, Mager D, et al. Regional variation in prescription use in the United States. Presented at: ISPOR 4th Annual European Congress, Cannes, France, 12 November 2001